Drug intelligence / Profile preview

shRNA PD-L1

Development stage
Preclinical
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral, Intralesional, Intraperitoneal, Intramuscular, Intradermal, Oral, Parenteral, Implant
01

Overview

shRNA PD-L1 refers to short hairpin RNA designed to target and silence the expression of programmed death-ligand 1 (PD-L1). PD-L1 is a key immune checkpoint protein that is frequently upregulated on the surface of tumor cells, allowing them to evade immune detection by binding to PD-1 on T cells. In addition to its role in immune evasion, tumor-intrinsic PD-L1 has been shown to promote tumor-initiating cell generation, epithelial-to-mesenchymal transition (EMT), cell proliferation, and migration. Silencing PD-L1 using shRNA is widely utilized in preclinical research to investigate these cell-autonomous roles of PD-L1 and to evaluate the therapeutic potential of gene-silencing approaches in various cancers, including triple-negative breast cancer, melanoma, and ovarian cancer.

Other names
PD-L1 shRNAPD-L-1 shRNAPD-L 1 shRNAPD-L1-shRNAPD-L-1-shRNAPD-L 1-shRNAshort hairpin RNA targeting PD-L1shRNA-mediated PD-L1 silencing
02

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on shRNA PD-L1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on shRNA PD-L1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call